Cyclosporine bioavailability: Dosing implications and impact on clinical outcomes in select transplantation subpopulations

Clinical Transplantation

Volumn 10, Issue 1 I, 1996, Pages 55-59

  First, M Roy ^a   Schroeder, Timothy J ^a   Monaco, Anthony P ^b   Simpson, Mary Ann ^b   Curtis, John J ^c   Armenti, Vincent T ^d  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bioavailability; Cyclosporine; Diabetics; Pregnancy; Race

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEGRO; PRIORITY JOURNAL; RACE DIFFERENCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PREGNANCY; TREATMENT OUTCOME;

EID: 0029868808     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. MEYER MM, MUNAR M, UDEAJA J, BENNFTT W. Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 1993: 4: 1306
2. LINDHOLM A, HENRICSSON S, LIND M, DAHLQVIST R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 1988: 34: 461.
3. OHLMAN S, LINDHOLM A, HÄGGLUND H, SÄWE J, KAHAN BD. On the intraindiviaual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur J Clin Pharmacol 1993: 44: 265.
4. KASISKE BL, HEIM-DUTHOY K, RAO KV AWNI WM. The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988: 46: 716.
5. LINDHOLM A, KAHAN BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993: 54: 205.
6. ALMOND PS, MATAS A, GILLINGHAM K, et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993: 55: 752.
7. BASADONNA GP, MATAS AJ, GILLINGHAM KJ, et al. Relationship between early vs late acute rejection and onset of chronic rejection in kidney transplantation. Transplant Proc 1993: 25: 910.
8. SCHROEDER TJ, HARIHARAN S, FIRST MR. The relationship between cyclosporine (CyA) bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994: 26: 2787.
9. LINDHOLM A, OHLMAN S, ALBRECHTSEN D, TUFVESON G, PERSSON H, PERSSON NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993: 56: 307.
10. TESI RJ, HENRY ML, ELKHAMMAS EA, FERGUSON RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplantation 1993: 7: 345.
11. MUNSON JL; BENNETT WM, BARRY JM, NORMAN DJ. A case control study of renal transplantation in patients with type I diabetes. Clin Transplantation 1992: 6: 306.
12. MONACO AP, SAHYOUN AI, MADRAS PN, et al. Cyclosporine in multi-drug therapy in living-related kidney transplantation. Clin Transplantation 1990: 4: 347.
13. MONACO AP. Cyclosporine dosing in diabetic renal transplant recipients. Presented at Cyclosporine Dosing Strategies in Long-Term Patient Management. May 17, 1994, Chicago. IL.
14. BUTKUS DE, MEYDRECH EF, RAJU SS. Racial differences in the survival of cadaveric renal allografts: Overriding effects of HLA matching and socioeconomic factors. N Engl J Med 1992: 327: 840.
15. LINDHOLM A, WELSH M, ALTON C, KAHAN BD. Demographic factors influencing Cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability. Clin Pharmacol Ther 1992: 52: 359.
16. LINDHOLM A, WELSH M, RUTZKY L, KAHAN BD. The adverse impact of high Cyclosporine clearance rates on the incidences of acute rejection and graft loss. Transplantation 1993: 55: 985.
17. VAN BUREN DH, RICHIE RE, NYLANDER W, et al. Single-center analysis of impact of immunosuppressive therapy upon renal allograft survival in the black population. South Med J 1991: 84: 715,
18. CURTIS JJ. Cyclosporine dosage and blood levels in African-American and white recipients of living-related donor kidney transplants. Presented at Cyclosporine Dosing Strategies in Long-Term Patient Management, May 17, 1994, Chicago, IL.
19. BOURGET P, FERNANDEZ H, DELOUIS C. Accumulation of Cyclosporine in the conceptus during the first trimester of pregnancy after liver transplantation. Transplantation 1991: 51: 1306.
20. BIESENBACH G, ZAZGORNIK J, KAISER W, et al. Cyclosporin requirement during pregnancy in renal transplant recipients. Nephrol Dial Transplant 1989: 4: 667.
21. MUIRHEAD N, SABHARWAL AR, RIEDER MJ, et al. The outcome of pregnancy following renal transplantation. The experience of a single center. Transplantation 1992: 54: 419.
22. ARMENTI VT, AHLSWEDE KM, AHLSWEDE BA, et al. Variables affecting birthweight and graft survival in 197 pregnancies in cyclosporine-treated female kidney transplant recipients. Transplantation 1995: 57: 476.